Mitapivat: A Breakthrough Oral Treatment for Transfusion-Dependent Thalassaemia

Mitapivat, an oral pyruvate kinase activator taken twice daily, demonstrated a statistically significant reduction in transfusion burden for patients with severe inherited blood disorders, according to clinical trial data published in The Lancet. The Phase 3 trial, known as ENERGIZE-T, evaluated 258 adult patients diagnosed with either α-thalassaemia or β-thalassaemia who required regular, lifelong red blood cell transfusions. Thalassaemias are monogenic inherited diseases characterized by a reduced production of globin chains of haemoglobin, leading to chronic anemia and ineffective red blood cell production. Patients in the study received either 100 mg of mitapivat twice daily or a matched placebo on a 2:1 randomization ratio over a 48-week double-blind treatment period. Lifelong red blood cell transfusions routinely required by severe thalassaemia patients result in dangerous iron overload.

Mechanisms of Pyruvate Kinase Activation

Mitapivat functions by allosterically binding to the pyruvate kinase enzyme, stabilizing it and increasing its enzymatic activity. This targeted action drives greater adenosine triphosphate (ATP) production inside red blood cells, which extends the cellular lifespan of these fragile blood components.

In thalassaemia, an underlying imbalance in haemoglobin chains causes premature red blood cell destruction. By boosting cellular energy metabolism and slowing cell destruction, mitapivat attacks the pathology at a mechanistic level rather than merely compensating for resulting anemia.

Regulatory Milestones and Trial Design

The ENERGIZE-T study utilized a transfusion burden primary endpoint rather than relying on short-term hemoglobin measurements. Agios Pharmaceuticals designed the 48-week trial to demonstrate disease-modifying capabilities in a rare hematology population that traditionally relies on hospital visits every three to four weeks.

The United States Food and Drug Administration approved mitapivat under the brand name AQVESME on December 23, 2025. Regulatory documentation describes the approval as the first oral treatment for anemia in adults with beta-thalassaemia and the first drug approval of any kind for adults with alpha-thalassaemia.